People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Pharmaceuticals, Biotechnology, Other, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. | — | Pharmaceuticals | Series C | $128.2M | $2.1B | 2019 |
| Frontier Medicines Corp | — | Biotechnology | Series C | $122.0M | $2.5B | 2019 |
| Oncorus, Inc. | — | Other | Series C | $115.1M | $921.8M | 2016 |
| ReShape Lifesciences Inc. | — | Other Health Care | Series C | $113.8M | $63.9M | 2009 |
| Blade Therapeutics, Inc. | — | Biotechnology | Series B | $77.0M | $475.5M | 2016 |
| Redona Therapeutics, Inc. | — | Biotechnology | Series C | $66.8M | $76.1M | 2018 |
| Amphivena Therapeutics, Inc. | — | Biotechnology | Series B | $65.2M | $1.5B | 2013 |
| Maverick Therapeutics Inc. | — | Biotechnology | Series C | $56.0M | $2.3B | 2017 |
| Potenza Therapeutics, Inc. | — | Pharmaceuticals | Series B | $35.0M | $170.0M | 2014 |
| Vesuvius Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $10.2M | $316.7M | 2014 |
| CoStim Pharmaceuticals Inc. | — | Pharmaceuticals | Series A | $10.0M | $309.9M | 2013 |
| Trieza Therapeutics, Inc. | — | Pharmaceuticals | Series A | $6.0M | $185.8M | 2016 |
Luke Evnin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Luke Evnin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Cordo | 4 | 6 |
| Daniel Hicklin | 4 | 4 |
| Cameron Wheeler | 3 | 9 |
| Briggs Morrison | 3 | 8 |
| Phil Gutry | 3 | 4 |
| Arnold Oronsky | 2 | 10 |
| Alon Lazarus | 2 | 7 |
| Sakae Asanuma | 2 | 6 |
| Kazumi Shiosaki | 2 | 4 |
| Marian Nakada | 2 | 4 |
| Jean-Francois Formela | 1 | 17 |
| Christoph Westphal | 1 | 8 |
| Derek DiRocco | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Josh Resnick | 1 | 7 |
| Elaine Jones | 1 | 6 |
| Paul Klingenstein | 1 | 6 |
| ERIC MOESSINGER | 1 | 6 |
| Mark McDade | 1 | 5 |
| Carl Goldfischer | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.